Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 79Lymphoid 56Other hematologic neoplasm 13Myeloid 2Classical hematology 2CNS 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 75pembrolizumab 60Bevacizumab 54Carboplatin 52Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 30olaparib 29Gemcitabine 27liposomal doxorubicin 26Biopsy 24Taxes 19Topotecan 17Nivolumab 17Doxorubicin 17Immunoglobulin G 15Cyclophosphamide 15Disulfides 14lenvatinib 13Letrozole 13Surveys and Questionnaires 12Radiotherapy 12niraparib 11fludarabine 11Platinum 11Drug Therapy 11atezolizumab 10abemaciclib 10Fulvestrant 9Docetaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lenalidomide × Gynecologic × 90 days × Clear all
NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡